Arvinas (NASDAQ:ARVN) has announced that the US Food and Drug Administration (FDA) has authorized the company’s investigational new drug application (IND) for ARV-471 to treat locally advanced or metastatic ER positive/HER negative breast cancer. As quoted in the press release: Arvinas expects to initiate a Phase 1 clinical trial for ARV-471 in the third quarter … Continued
The post Arvinas Authorized to Proceed with ARV-471 appeared first on Investing News Network.
Original Article: Arvinas Authorized to Proceed with ARV-471